John Crown Clinical Oncology Society of Australia Annual Scientific Meeting 2023

Abstracts this author is presenting:

• A Phase 3 trial of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma — Lunch, Poster Viewing, Exhibition & COSA Group Meetings
• A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: poor prognosis subgroup analysis — Lunch, Poster Viewing, Exhibition & COSA Group Meetings
• Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: post-adjuvant PD-1 analysis — Lunch, Poster Viewing, Exhibition & COSA Group Meetings
• A Phase 3 trial comparing fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma — Lunch, Poster Viewing, Exhibition & COSA Group Meetings